Home Featured Page 225

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update

Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results

Filament Health Announces Q2 2021 Financial Results

PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of...

In Awe: Psychedelic Assisted Psychotherapy and the Mystical Experience

Myth Busting: Magic Mushroom Spores Have Little to do with Potency

Why Aren’t Psychedelic Drugs Prohibited in the 2021 Tokyo Olympics?

Enzymes Responsible for DMT Synthesis Coexist in Mammalian Brain Cells

More Details on the Psilocybin Mushroom Bluing Reaction

Why Don’t Magic Mushroom Spores Contain Psilocybin?

1...224225226...296 Page 225 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update

Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results

Filament Health Announces Q2 2021 Financial Results

PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of...

In Awe: Psychedelic Assisted Psychotherapy and the Mystical Experience

Myth Busting: Magic Mushroom Spores Have Little to do with Potency

Why Aren’t Psychedelic Drugs Prohibited in the 2021 Tokyo Olympics?

Enzymes Responsible for DMT Synthesis Coexist in Mammalian Brain Cells

More Details on the Psilocybin Mushroom Bluing Reaction

Why Don’t Magic Mushroom Spores Contain Psilocybin?

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY